Andilab, Ruffamae .

HRN: 27-33-83  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/17/2025
CEFUROXIME 500MG (TAB)
06/17/2025
06/23/2025
ORAL
500mg
BID
Sp NSVD With RMLE
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: